Sort   by:  
 Page size 
MetabolomicsThe impact of nutritional supplementation on sweat metabolomic content
Sweat is emerging as a prominent biosource for real-time human performance monitoring applications. Although promising, sources of variability must be identified to truly utilize sweat for biomarker applications. In this proof-of-concept study, a targeted metabolomics method was applied to sweat col...
2021-03-15 | MTBLS2427 | MetaboLights
UnknownOlaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
Not available
S-EPMC8144220 | biostudies-literature
UnknownMaternal genomic profile, gestational diabetes control, and Mediterranean diet to prevent low birth weight.
Not available
S-EPMC11648256 | biostudies-literature
TranscriptomicsTranscription profiling of mouse cerebral cortex using two model strains (C57BL/6 and ApoE(-/-) on the C57BL background) upon episode hypoxia treatment
Study the gene expression variation at cerebral cortex using two mouse model strains (C57BL/6 and ApoE(-/-) on the C57BL background) upon episode hypoxia treatment
ORGANISM(S): Mus musculus 
2013-01-30 | E-TIGR-135 | biostudies-arrayexpress
UnknownHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Not available
S-EPMC2579381 | biostudies-literature
UnknownPARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Not available
S-EPMC9225208 | biostudies-literature
UnknownLoss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Not available
S-EPMC7518105 | biostudies-literature
UnknownAn Early Mediterranean-Based Nutritional Intervention during Pregnancy Reduces Metabolic Syndrome and Glucose Dysregulation Rates at 3 Years Postpartum.
Not available
S-EPMC10383706 | biostudies-literature
ProteomicsShieldin complex promotes DNA end joining and counters homologous recombination in BRCA1-null cells
BRCA1 deficiencies cause breast, ovarian and other cancers, and render tumours hypersensitive to PARP-inhibitors. To understand resistance mechanisms, we conducted whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in BRCA1-deficient breast cancer cells treated with PARP-inhibitors. Thu...
ORGANISM(S): Homo sapiens (Human) 
2018-05-31 | PXD009830 | Pride
C20orf196 Shieldin Fam35a 
UnknownPilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Not available
S-EPMC6657121 | biostudies-literature
Sort   by:  
 Page size